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Abstract
Purpose To assess the clinical effectiveness and cost-effectiveness of meniscal allograft transplantation (MAT) after menis-
cal injury and subsequent meniscectomy.
Methods Systematic review of clinical effectiveness and cost-effectiveness analysis.
Results There is considerable evidence from observational studies, of improvement in symptoms after meniscal allograft 
transplantation, but we found only one small pilot trial with a randomised comparison with a control group that received 
non-surgical care. MAT has not yet been proven to be chondroprotective. Cost-effectiveness analysis is not possible due to 
a lack of data on the effectiveness of MAT compared to non-surgical care.
Conclusion The benefits of MAT include symptomatic relief and restoration of at least some previous activities, which will 
be reflected in utility values and hence in quality-adjusted life years, and in the longer term, prevention or delay of osteoar-
thritis, and avoidance or postponement of some knee replacements, with resulting savings. It is likely to be cost-effective, 
but this cannot be proven on the basis of present evidence.
Level of evidence IV.
Keywords Meniscal allograft transplantation · Cost-effectiveness
Introduction
The meniscal cartilages spread the weight-bearing forces 
in the knee, thereby preserving the articular cartilage on 
femoral condyles and tibial plateau. The lateral meniscus is 
thought to carry approximately 70% of the load in its com-
partment, and the medial one 50%, when the leg is straight. 
Hannon et al. [18] and the IMREF 2015 Consensus state-
ment [16] have provided reviews of the history of menis-
cectomy and of meniscal allograft transplantation (MAT).
Meniscal injury and subsequent meniscectomy is thought 
to lead to early osteoarthritis (OA) because of increased 
stress on the central articular cartilage. The articular car-
tilage under the menisci is thinner than on other parts of 
the tibial plateau [56] and so the sub-meniscal region is 
more at risk of OA if the meniscus is removed. Because 
acute meniscal injuries often occur in sport, those afflicted 
are often young. For example, in the case series of 63 
patients reported by Cameron and Saha [10] the average 
age at meniscectomy was 24. An even younger cohort was 
reported by Pengas et al. (from the 1960s and 1970s) [36] 
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in which 313 patients with mean age 16 (range 10–19) at 
meniscectomy were followed up for about 40 years (mean 
age at assessment 57, range 43–67). OA was found in 87% 
of meniscectomised knees but in only 18% of non-operated 
knees. All were either symptomatic (mean KOOS 70) or 
(13%) had had knee replacement.
Acute meniscal injuries due to trauma in young people 
should be distinguished from the degenerative meniscal 
lesions that are common in older people—25% in age range 
50–59 years, increasing to 45% in those aged 70–79. The 
ESSKA 2016 consensus [7] was that meniscectomy should 
not be a first-line treatment in degenerative meniscal lesions.
Several authors have asserted that meniscectomy leads 
to OA [4, 13, 21], but the evidence is mixed for several rea-
sons. One is duration of follow-up. Jackson [20] reviewed 
577 knees after meniscectomy and compared them with 
the patients’ other knees. Definite radiographic degenera-
tive changes were much more common in meniscectomised 
knees (21% versus 5%) but took time to develop, being 
seen in 22% (control knees 4%) at under 20 years, 53% at 
20–29 years (controls 13%) and 67% at 30–40 years. How-
ever, only about half of those with radiological degeneration 
had painful knees.
Given what is known about the functions of the menis-
cus, meniscectomy would be expected to increase the risk of 
osteoarthritis (OA). However, for assessing the cost-effec-
tiveness of MAT in reducing OA, we need to know the risks 
of OA after meniscectomy with and without MAT.
The systematic review by Smith et al. [46] concluded that 
in 35 studies with mean follow-up 5.9 years, there was good 
evidence that MAT improved symptoms after meniscectomy, 
but that there was insufficient evidence as to whether MAT 
would be chondroprotective. Smith et al. noted the lack of 
randomised controlled trials (RCTs) of MAT versus con-
servative care. It would be much easier to quantify the effect 
of MAT on OA if data were available on matched patients 
that did not have MAT.
One problem, as Ahn et al. [4] have pointed out, is that 
patients having meniscectomy may have sustained articular 
damage in the same event that led to meniscal injury. So OA 
in a meniscectomised patient may not be due entirely to the 
absence of a meniscus. However, in the study by Roos et al. 
[40], 19% had evidence of articular cartilage damage at the 
time of meniscectomy but 71% had OA in the knees 21 years 
later, with 48% having Kellgren and Lawrence (KL) grades 
of 2 or worse. Roos et al. compared the prevalence of OA in 
meniscectomised knees to those in a population-based con-
trol group, in which any OA was seen in 18% and KL grade 2 
or worse in 7%. Unfortunately the response rate amongst the 
invited controls was under 40%, and those who responded 
may have had more knee pathology, and hence interest, than 
those who did not. Roos et al. make a useful point about 
using contralateral knees in meniscectomised patients for 
control purposes, because the other knees had higher rates 
of OA than the control group, relative risk (RR) 1.5 for any 
OA. So it could be argued that using contralateral knees 
as controls may under-estimate the effect of meniscectomy. 
Conversely, if the contralateral knees have an increased risk 
of OA, some of the OA seen in the meniscectomised knee 
may not be due to the meniscectomy. It is known that OA 
in one knee causes ‘overloading’ of the other side (that is, 
OA in the contralateral knee may be blamed on OA in the 
meniscectomised joint), but not the degree to which this is 
important, over and above a person’s pre-determined genetic 
tendency to OA [30].
Another issue is how OA is determined—radiological or 
symptomatic. In a study of elite American football play-
ers with mean age 23 by Smith et al. [45], OA was defined 
as moderate-to-severe non-focal articular cartilage loss on 
MRI or joint space narrowing on plain radiographs. They 
were selected for imaging because they had had previous 
surgery or had knee symptoms. OA was seen in 15%, but in 
4% of those with no previous knee surgery and in 27% of 
those who had had partial meniscectomy. Mean BMI was 32. 
Their symptom scores were not reported, but all were still 
functioning at a high level.
Paradowski et al. [34] also assessed OA by radiology, 
defining it as joint space narrowing or the presence of osteo-
phytes, equivalent to KL stage 2, in cohorts from 1973, 1978 
and 1983–1985. Follow-up varied in duration, as did the 
type of meniscectomy, with total or subtotal in the early 
years, but with more (35%) partial meniscectomy in later 
years. Mean age at meniscectomy was 35 years, and at fol-
low-up 60 (range 34–85) years. Radiographs of the other 
knees were also taken. The prevalence of tibio-femoral OA 
at last follow-up was 68% in the meniscectomised group 
and 36% in the other knees (some of which may have had 
other surgery).
Claes et al. [12] carried out a meta-analysis of 16 studies 
of OA after anterior cruciate ligament (ACL) reconstruction, 
with a minimum follow-up of 10 years, published before 
October 2010. 11 studies with 614 patients were used for 
analysis of the effect of meniscectomy. There was consider-
able heterogeneity amongst studies, but this was in effect 
size not direction. The overall OR for OA after meniscec-
tomy was 3.5 [95% confidence interval (CI) 2.6–4.9], with 
OA seen in 50% after meniscectomy and in 16% in control 
knees.
Other variables that affect the incidence of OA include 
which cartilage was removed, and whether there is varus 
or valgus mal-alignment. Allen et al. [5] followed up 230 
patients who could be traced out of a series of 428 who had 
meniscectomy in the years 1958–1970. Some had died but 
210 (49% of the original cohort) were reviewed 10–22 years 
post-meniscectomy. Age at meniscectomy ranged from 13 to 
67 years and at follow-up from 29 to 85 years. Radiographs 
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were obtained of both knees. Over half the meniscectomised 
knees were clinically normal at mean follow-up of 17 years, 
but radiological signs of OA were seen in 18% of menis-
cectomised knees compared to 5% of the control knees. OA 
was more frequent after lateral meniscectomy than medial, 
presumably because the lateral meniscus covers more of the 
tibial plateau. After lateral meniscectomy, OA was more 
common in valgus knees, and after medial meniscectomy, 
OA was more common in varus knees.
The lateral meniscus is normally crescent shaped but is 
occasionally larger, even a complete circle. This is known 
as a discoid cartilage, and may be more prone to injury. 
Ramme et al. [37] compared the cost-effectiveness of MAT 
and partial meniscectomy in young women with torn discoid 
lateral meniscus and concluded that MAT was cost-effective.
Meniscectomy can be total or partial. Andersson-Molina 
et al. [6] noted radiographic changes 14 years after menis-
cectomy, including joint space narrowing in 13 of 18 
patients after total meniscectomy, but only 6 of 18 after par-
tial meniscectomy. Joint space narrowing was seen in seven 
patients after total meniscectomy but in only one who had 
partial meniscectomy. Andersson-Molina et al. [6] compared 
the meniscectomised group with 36 matched controls (from 
a local football club) with no history of knee injury, none of 
whom had joint space narrowing. Despite the radiographic 
changes, about 70% of the meniscectomy group had normal 
Lysholm scores at 14 years.
Rongen et al. [39], using data from the Osteoarthritis Ini-
tiative, found that meniscectomy conferred a hazard ratio for 
OA of 3.03 compared to a matched group that had not had 
meniscectomy. The meniscectomised group (335 patients) 
had a higher rate of total knee replacement (TKA) than the 
controls, 18% versus 11%. However, this study is perhaps 
not as relevant to this review as some others, because the 
patients studied were in age range 45–79, so many would 
have had degenerative change in their menisci rather than 
acute trauma.
A key question is quantifying the risk of OA after menis-
cectomy compared to knees that do not have meniscectomy. 
Table 1 shows some relative risk ratios at different intervals 
with fair consistency in the relative risks ranging from 3.1 
to 5.8.
The IMREF 2015 Consensus statement [16] concluded 
that meniscectomy increases the risk of OA, and recom-
mended three main indications for MAT:
• Unicompartmental pain following total or defunctioning 
subtotal meniscectomy.
• As a concomitant procedure to ACL reconstruction in 
order to prolong the life of ACL reconstruction.
• As a concomitant procedure to articular cartilage repair 
in a meniscus-deficient compartment.
However, the IMREF consensus recommended that MAT 
was not indicated in patients with no meniscus but no symp-
toms. This could be seen as a problem given that people may 
be developing OA without symptoms in the early stages. The 
decision was based on a paucity of evidence of chondropro-
tective benefit in asymptomatic people, and consideration of 
the significant re-operation rate after MAT (as high as 35%).
Some authorities recommend MAT only in knees with 
little or no degenerative change [56].
The aim of this study was to assess the cost-effectiveness 
of MAT after meniscectomy. The benefits of MAT could 
be, firstly relief of symptoms and restoration of quality of 
life, and secondly, avoidance or delay in the development 
of symptomatic osteoarthritis and the subsequent need for 
knee replacement.
Materials and methods
A systematic review of clinical effectiveness was carried 
out. A number of recent systematic reviews were identified, 
their quality assessed, and their conclusions summarised. A 
table of studies included in these reviews was created. Their 
inclusions varied because their topics of interest varied. A 
search for recent studies not included in those reviews was 
carried out to update them. Greater weight was given to pro-
spective studies.
Fuller details of methods are given in the full report on 
the ESSKA website, but in brief;
• The databases Ovid Medline, Ovid Embase, Web of Sci-
ence and the Cochrane Library were searched for articles 
published from the year 2000 until February 15th 2018. 
The Medline search strategy and the numbers of records 
Table 1  Risk of osteoarthritis after meniscectomy
OA after 
meniscec-
tomy
OA no 
meniscec-
tomy
Relative risks
Duration of follow-up
 10–19 years
  Allen et al. [5] 18% 5% 3.6
  Jackson et al. [20] 23% 4% 5.8
 20–29 years
  Jackson et al. 53% 13% 4.1
 40 years
  Pengas et al. [36] 87% 16% 4.8
 >10 years
  Claes et al. [12] 50 16 3.1
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obtained are shown in Appendix 1 to the Supplementary 
files.
• Titles and abstracts of retrieved studies were screened 
by two people, with full papers obtained if inclusion or 
exclusion was uncertain from the abstract.
• Standard systematic review methods were used with 
quality assessment of included studies using standard 
checklists for both reviews and primary studies, and 
checking of data extractions by a second reviewer.
Data were sought on:
• Quality of life, preferably using a generic preference-
based measure or a condition-specific measure that could 
be mapped to a utility measure such as EQ-5D.
• Data on failures and reoperations and graft survival.
• The development of OA, and the frequency of knee 
replacement, either unicompartmental or total.
• Data on costs, both short-term (the costs of MAT), 
medium term (the cost of treatment of both those having 
MAT and those having non-operative care) and long-
term (the costs of OA and arthroplasty).
All included studies were assessed for methodological 
quality using recommended criteria. The Cochrane risk 
of bias (ROB) assessment criteria [19] were to be used 
for RCTs and controlled clinical trials (CCTs). Six possi-
ble biases were assessed: selection bias, performance bias, 
detection bias, attrition bias, reporting bias and other bias. 
For non-randomised studies, tools developed by the National 
Institute for Health, National Heart, Lung and Blood Insti-
tute (NIH NHLBI) [31] re used. These tools focus on biases 
(selection, performance, detection and attrition), confound-
ing, power and strengths of associations between treatments 
and outcomes. The tools for cohort studies cover two group 
comparisons, before and after studies (one group) and case 
series studies (one group, no before measure).
Results
Thirty-seven papers from 19 studies of MAT were included, 
the main papers being references [1, 2, 11, 13, 17, 22, 24, 
28, 29, 32, 33, 35, 38, 42, 43, 48, 49, 51, 52, 54] (full list of 
articles in supplementary file).
There was a range of study designs (Supplementary file, 
Table 1), with one cohort study (with comparator group but 
the comparison was not relevant to the review), 12 single 
arm before and after studies (which report variables at both 
baseline and follow-up), and six case series. Study char-
acteristics and baseline characteristics of the participants 
are summarised in the Supplementary file, Table 2. Defi-
nitions of failure and periods of follow-up varied, and are 
summarised in Supplementary file Tables 2 and 3. Mainly 
because of the observational design, the quality of these non-
randomised studies was mostly graded fair, with only two 
studies [28, 29] rated as good, because they reported inter-
vention and results more clearly, and two studies rated as 
poor due to insufficient reporting of selection criteria, high 
loss to follow-up and lack of blinding of outcome assessors 
[11, 24] and lack of statistical comparison before and after 
the intervention [11]. Interpretation of some studies was 
complicated by other procedures, for example in the study 
by Saltzman et al. study [43] all patients in the full thickness 
defect arm had cartilage repair procedures, mainly osteo-
chondral allograft. A publication from the study by Saltz-
man et al. [44] reported outcomes for 40 patients undergoing 
concomitant MAT and anterior cruciate ligament reconstruc-
tion. Where reported, around 20–60% of people underwent 
concomitant procedures. Further details are provided in the 
Supplementary file, Table 2.
Cohort size in the included studies ranged from 30 to 313, 
with a total of 1731 people undergoing at least one MAT. 
Twelve of the studies were conducted in the USA. Average 
follow-up in the studies ranged from 2.5 years to 17.3 years, 
although there was a large variation in the ranges. The key 
indications for MAT or study inclusion criteria are given in 
Supplementary file Table 2, but the usual indication was per-
sistent symptoms after meniscectomy. Some studies (such as 
[13]) included only patients with relatively well-preserved 
articular cartilage, or well-aligned knees [17], but others 
included people with more evidence of advanced OA [43, 
49] partly to assess survival of MAT in the knees with OA. 
Marcacci et al. [28] required the other knee to be healthy. 
Rue et al. [42] included people undergoing simultaneous 
combined MAT and cartilage repair procedures includ-
ing autologous chondrocyte implantation (ACI) or fresh 
osteochondral allograft (OCA) transplantation, in the same 
compartment. Abrams et al. [2, 3] included people undergo-
ing combined MAT and OCA transplant. A proportion of 
the people in the remaining studies underwent a variety of 
concomitant procedures (around 31–73%); these are sum-
marised in Supplementary file Table 2. Mean age mostly 
ranged from 25 to 45 years, although in the study by Stone 
et al. [48] the mean age was 47 years. The study by Riboh 
et al. [38] included only adolescents, age range 13–16 years. 
The proportion of men in the studies ranged from 48 to 80%, 
with the majority of studies having at least 60% men, except 
for 28% in the study of adolescents. [38].
Failure and survival
The definitions of failure used in the studies differed, and 
included need for revision surgery (MAT or TKA), removal 
of graft, and persistent pain (Supplementary file Table 3).
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Graft failure, as shown in Table 2, ranged from 3.6% 
in the bony-fixation subgroup of Abat et al. [1] (success 
defined as patient satisfaction at 5 years follow-up) to 29% 
in the studies by Van der Wal (13.8 years of follow-up) [53]. 
Kempshall et al. [22] found that when failure occurred it 
was early, potentially indicating a problem with healing or 
integration of the graft, and reported a mean time to failure 
of 1.12 years (range 0.47–1.85; SD 0.55). Time to failure 
ranged from mean 5.2 years in the study by Stone et al. [49] 
to 10.3 years in the one by Van der Wal [53]. These rates 
reflect the baseline state of the knees, with the patients in the 
Stone et al. study having significant OA.
The results of the Kempshall et al. study [22] show that 
MAT gives better results in terms of failure rates, if done 
before the articular cartilage is advanced to the stage of bare 
bone, with 2-year survival 98% amongst those with articu-
lar cartilage in good condition, versus 78% in those with 
poor condition, but even then it was beneficial with similar 
absolute increases in clinical scores, though from different 
baselines. The more advanced group had more concomitant 
procedures (about 80% compared to 35% in the good car-
tilage group) with the difference mainly in microfracture.
From the same group, Parkinson et al. [35] reported the 
results of a series of 125 MATs over a 10-year period, with 
Table 2  Failure rates in MAT studies
HSS Hospital for special surgery, KASS knee assessment scoring system, TKA total knee arthroplasty, UKA unicompartmental knee arthroplasty, 
ND no chondral defect, FTD full thickness chondral defect
Study Number of MATs Mean FU (range) years Defn failure Proportion failed
Abat et al. [1], González-
Lucena et al. [17]
88 5 years (2.5–10) Removal of graft Suture only 9%
Suture fixation 33 Bone fixation 3.6%
Bony fixation 55
Cole et al. [13] 40 2.8 years (2–4.8) Conversion to KA 7.5%
Kim et al. [23] 110 4.1 years (2–13.7) Poor clinical results 10.9%
Failure (resection, TKA, poor Lysholm) 2% 10 year, 7% 15 years
Marcacci et al. [28] 32 3.4 years (3–5.5) Debridement, meniscectomy or poor 
result
6.3%
Mahmoud et al. [27] 45 8.6 years (SD 3.4) Removal of MAT or KA OCS 0–2 no failures
OCS 3–4 26%
McCormick et al. [29] 200 4.9 years (2–9.8) Revision MAT or TKA 4.7%
1.5% conversion to KR
Noyes et al. [33] 40 3.3 years (2.0–5.8) 7.9%
Noyes and Barber-Westin [32] 58 17.3 years Persistent pain or detached or torn 
allograft
15.3%
Parkinson et al. [35] 124 3 years (1–10) Graft removal, revision MAT or KA 10.5%
Riboh et al. [38] 32 7.2 years (2–15) Not reported (but revision MAT was an 
outcome
22%
Rue et al. [42] 31 3.1 years Revision or removal 6%
Saltzman et al. [43] ND 22 ND 4.5 years Revision MAT or ND 15%
FTD 69 FTD 2.5 years KA FTD 16.2%
MAT + ACL 40 MAT + ACL 5.7 years MAT + ACL 20%
Stone et al. [48] 119 5.8 years (0.2–12.3) Removal of the allograft without revi-
sion, removal and new MAT, or KA
20.1%
Stone et al. [49] 49 8.6 years (2–15) KA, removal of MAT, pain greater than 
pre-operatively, or constant moderate 
pain with no relief from non-operative 
treatment
22.4%
Van der Wal et al. [53] 63 13.8 years (SD 2.8) Persistent pain, unsuccessful KASS, 
poor Lysholm score, detached allograft 
(2002); removal of MAT, UKA or 
TKA (2009)
29%
Van der Straeten et al. [52] 329 6.8 (0.2–24.3) Removal of MAT, KA 27.4%
19% to KR
Verdonk et al. [54] 100 7.2 years (0.5–14.5) HSS pain subscore < 30, HSS function 
score < 80, KR
Medial 28%, lateral 16%
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median follow-up 3 years but range 1–10 years. Those with 
ICRS grade 3b changes (full thickness articular cartilage loss 
on either femoral condyle or tibial plateau or both) had much 
higher failure rates 5 years after MAT. The Kaplan–Meier 
survival curves show most failures (defined as a need for 
removal or revision of the MAT or knee replacement) 
occurred in the first 4–5 years. Survival was better with 
lateral than with medial allografts. The mean age at menis-
cectomy was 24 and at MAT 31 years (range 8–49 years). 
However, even in the worst group with bare bone on both 
femur and tibia, the 5-year MAT survival was 62%. Most 
failures occurred in the first few years.
The proportions having reoperations, including revi-
sion MAT, debridement or removal of the allograft, varied 
amongst studies, partly because of duration of follow-up. 
In their study of 329 MAT implants, Van der Straeten et al. 
[52] reported that 27% of allografts were removed after a 
mean time in situ of 8.5 years. In the study of 200 patients 
by McCormick et al. [29], 32% had subsequent surgery by a 
mean follow-up 6 years, with mean time to re-operation 21 
(range 2–107) months. Abat et al. [1] and González-Lucena 
et al. [17] reported that 21.4% and 7.3% of the suture-only 
(by 6.5 years) and bony-fixation groups (by 5 years), respec-
tively, underwent revision surgery involving refixation or 
removal of the allograft. Carter et al. [11] found 17.5% had 
had partial meniscectomy by 10 years of follow-up. Noyes 
and Barber-Westin [32] reported that during 15 years fol-
low-up of 69 patients, half required reoperation relating to 
failure of the transplant (removal 15, revised 6, TKA 10, 
osteotomy 2, unicompartmental knee arthroplasty (UKR) 
4). In the study in adolescents by Riboh and colleagues [38] 
only two of 32 MATs required meniscal re-operation after 
mean follow-up of 7 years.
Repeat MATs were performed in 2% of cases by van der 
Straeten et al. [52], in 6% by McCormick et al. [29], in 10% 
(4 of 40 MATs) by Noyes and Barber-Westin [32], and in 
10% (5 of 49) by Stone et al. [49], and 12% in the study by 
Saltzman et al. [43]. Three studies reported no repeat MATs 
[1, 11, 38].
Conversions to TKA or UKA varied with duration of 
follow-up, being reported in 3% of cases in the study by 
Saltzman et al. [43] after a mean follow-up of 4 years, 6% 
in the study by McCormick et al. [29] by 6 years, 7% in the 
study by Cole et al. [13] with mean follow-up 33 months, 
Table 3  Long-term survival of MAT
Noyes and Barber-Westin [32] worst case includes some patients with no symptoms related to the transplant but who have MRI grade-3 signal 
intensity, major extrusion or a tear, signs of a meniscal tear on clinical examination; or radiographic complete loss of joint space. Clinical fail-
ures include transplant removal or revision, total or unicompartmental knee replacement, osteotomy, or pain with daily activities
Figures for Stone and Van der Straeten 5, 10 and 15 years, taken from KM graphs and are approximate
Parkinson et al. Baseline data. Group 1 intact articular cartilage or partial thickness loss. Group 2 full thickness loss on one condyle. Group 3 
full thickness loss on both condyles. Kim defined failure defined as resection of graft, conversion to THA, or Lysholm score < 45 or less than 
before MAT
a McCormick—but 32% had subsequent surgery usually debridement
Study Survival at 5-year time periods
5 years 10 years 15 years 20 years
Kim et al. [23] subgroup with ≥ 8 years follow-up (%) 98 93
Parkinson et al. [35]
 Group 1 (%) 97
 Group 2 (%) 82
 Group 3 (%) 62
 Mahmoud [27] 92% (from graph) 75% (from graph)
 McCormick et al. [29] 95%a 93% (from graph)
Noyes and Barber-Westin [32]
 Worst case (%) 77 45 19
 Clinical failures (%) 84 64 50
 Saltzman et al. MAT + ACL [44] (%) 84 45
 Van der Wal et al. [53] 95% (from graph) 67% (76% lateral, 56% 
medial)
53%
 Van der Straeten et al. [52] 80% 75% 50% 15% at 24 years
 Verdonk et al. [54] At 14 years
 Lateral MATs (n = 61) (%) 90 70 70
 Medial MATs (n = 39) (%) 86 74 53
 Medial MATs with high tibial osteotomy (n = 13) (%) 100 83 83
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19% in the Van Der Straeten et al. study [52] at a mean of 
11.5 years, and 25% by 15 years in the study by Noyes and 
Barber-Westin. [32].
Nine studies reported Kaplan–Meier survival analysis at 
various time points as shown in Table 3. 5-year survival 
rates were very good, but varied amongst group according 
to the state of chondral surfaces at baseline, as shown in the 
group with full thickness chondral loss on both condyles in 
the study by Parkinson et al. [35]. Ten-year survival ranged 
from 45% in the “worst case” results from Noyes and Barber-
Westin [32] to over 90% in two studies [23, 29], but most 
studies reported survival in the 60–75% range. However, as 
Noyes and Barber-Westin [32] report, some of the failures in 
their worst-case scenario were found only on radiographic 
or MRI imaging, in patients with no symptoms.
15-year survival ranged from 19 to 93%, but the 19% 
was in the Noyes and Barber-Westin worst-case scenario, 
whereas the clinical survival rate was 50% [32]. Most stud-
ies reported about half of the MATs surviving at 15 years.
Van der Straeten et al. [52] reported 15.1% survival at 
24 years, with a mean allograft survival time of 15.2 years.
So for economic analysis, it might be reasonable to 
assume around 20% have repeat surgery in the short-term 
but, based on the 15-year follow-up in the study by Noyes 
and Barber-Westin [32], around half in the longer term, but 
that clinical success rate at 15 years seems good compared 
to the natural history in untreated meniscectomised patients.
Progression of osteoarthritis
Carter et al. [11] reported that at 2 years, 5.9% had mild 
progression, by 10 years 44.1% had mild progression, 14.7% 
had moderate-to-advanced progression, and 41.2% had no 
change. Unfortunately, this study was reported only as an 
abstract. It reports that plain radiographs were obtained at 
2 and 10 years, but not whether progression was based only 
on radiography. Some X-ray progression is asymptomatic, 
as reported by Noyes and Barber-Westin [32]. It might be 
reasonable to assume that the 14.7% would need TKA but 
that the 44% with mild OA would get by with analgesics. 
The 14.7% is similar to the results of the 15-year follow-up 
by Noyes and Barber-Westin [32].
Verdonk et al. [57] reviewed 17 studies of radiological 
progression. Most studies were short-term (under 5 years) 
and showed no significant progress but the four studies with 
longer follow-up (10 years or longer) reported joint space 
narrowing in 48%, 67%, 75% and all patients.
The systematic review by Smith et al. [46] concluded that 
there was some evidence that MAT reduces progression of 
OA, but most studies had short durations of follow-up, the 
longest being a study by Verdonk et al. [55] with 12 years 
follow-up, though in that study 11 of the 41 patients also 
had tibial osteotomy.
In their study of 313 participants, van der Straeten et al. 
[52] reported progression of osteoarthritis as measured by 
the KL scale. At a mean of 6.8 years 40% of participants 
had no progression, 35% progressed more than grade 1, 20% 
more than two grades and 5% more than three grades.
Ahn et al. [4] reported the result of 69 MATs carried out 
by a single surgeon from 2005 to 2012. OA was defined 
by KL grade changes. Patients having any concomitant sur-
gery were excluded, as were patients with OA worse than 
KL grade 2. Most (about 80%) had KL 0 or 1. At 3-year 
follow-up, progression of OA was seen in 31 patients at aver-
age follow-up 5.5 years, but not in 38, mean FU 4 years. 
They noted that progression was more frequent after medial 
meniscectomy than lateral, with medial:lateral odds ratio 3.4 
(95% CI 1.2–9.3, p = 0.018). However, there were no differ-
ences in Lysholm or Tegner scores between the groups. Ahn 
et al. [4] concluded that it was possible that MAT reduced 
the risk of OA but that RCTs were necessary.
Functional outcomes
Table 4 shows results for functional outcomes. Nine stud-
ies reported Lysholm scores, all showing good results, 
with most reporting improvements of over 20 points. Eight 
reported International Knee Documentation Committee 
(IKDC) scores, with improvements ranging from 14.8 to 
29.8, with most studies reporting gains of over 20 points. 
Five studies showed improvements in Tegner scores.
The studies by Noyes et al. [33] and Noyes and Barber-
Westin [32], using the Cincinnati Knee Rating System 
(CKRS), reported statistically significant improvements in 
pain, swelling, perception, walking and stairs, but not in the 
knee giving way. LaPrade et al. [24] found a highly statisti-
cally significant improvement in the overall CKRS, from 
55 to 73.
Five studies [13, 22, 38, 42, 44] reported Knee Injury 
and Osteoarthritis Outcome Score (KOOS), and found sta-
tistically significant improvements in all subscales, except 
for the pain subscale in one small study in an adolescent 
population [38]. Another only reported the endpoint values 
and is of limited value [53]. In the study by Saltzmann et al. 
[44], the improvement exceeded the minimally clinically 
important differences on the symptoms and quality of life 
subscales in two subgroups that reported this, and in pain 
and sport in the full-thickness chondral defects subgroup.
Cole et al. [13] and Rue et al. [42] also reported statis-
tically significant differences in the Noyes symptom and 
sports activity scores.
The Western Ontario and McMaster Universities Arthri-
tis Index (WOMAC) was used in three studies [38, 44, 48] 
with some significant improvements in the function and total 
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scores (Supplementary file Table 6). Stone et al. [48, 50] 
found a significant (p < 0.001) improvement in overall score 
and pain after 10 years.
Kempshall et al. [22] reported outcomes by baseline 
articular cartilage state (Table 5) showing that end results 
were poorer in patients with more severe baseline articular 
cartilage damage than in those with good chondral sur-
face states., but they started with poorer scores and the 
actual improvements were of similar magnitude, for exam-
ple with improvements in Lysholm scores of 21.6 in the 
good baseline group (58.6–80.2) and 24 in the poor group 
(47.3–71.4), when grafts survived.
Mahmoud et al. [27] also noted greater improvements 
in Lysholm and IKDC scores in those with more advanced 
chondral damage at baseline (Table 4).
Table 4  Functional outcomes after MAT
Note 1: Where papers have not reported changes, these have been calculated but SDs, SEs and CIs are not available
NR not reported by study authors
Study (and number of initial patients) Baseline value (SD) Endpoint value (SD) Change (note 1) p value
Lysholm
 Abat et al. [1] n = 88 65.4 (11.6) 88.6 (7.2) 23.1 (NR) < 0.001
 Carter et al. [11] n = 40 47 (32–68) 71 (38–95) 24 (NR)
 Cole et al. [13] n = 36 52.4 (20.26) 71.6 (19.7) 19.2 (NR) < 0.05
 Kim et al. [23] modified Lysholm (n = 110) 73.2 (10.6) 89.4 (13.2) 16.2 (NR) < 0.001
 Marcacci et al. [28] n = 32 59.8 (18.3) 84.8 (14.4) 25 (NR) < 0.0001
 Saltzman et al. [43]
  ND (n = 22) 41.5 (22.3) NR 14.8 (14.4)a NR
  FTD (69) 43.4 (17.4) NR 21.1 (19.8)a NR
 Saltzman et al. [44]  MAT + ACL (40) 44 (16) 67 (22) 23 (NR) < 0.01
 Riboh et al. [38] 43.80 (20.37), n = 30 58.52 (17.92), n = 23 14.4 (NR) = 0.03
 Rue et al. [42] n = 28 48.7 (16.4) 74.0 (17.7) 25.3 (NR) < 0.001
 Van der Wal et al. [53] n = 49 36.36 (18) 61.06 (20) 24.7 (NR) 0.001
Baseline value (SD or 95% 
CI)
Endpoint value (SD or 95% 
CI)
Change (SD) p value
IKDC
 Carter et al. [11] n = 40 50.6 (32.2–68.9) 70.1 (39.1–93.1) 19.5 (NR)
 LaPrade et al. [24] n = 40 54.5 72.0 (n = 34) 17.5 (NR) < 0.001
 Marcacci et al. [28] n = 32 47.4 (20.6) 77.2 (15.6) 29.8 (NR) < 0.0001
 Rue et al. [42] n = 28 38.7 (12.7) 66.9 (17.2) 28.2 (NR) < 0.001
 Saltzman et al. [43]
  ND, n = 22 41.5 (22.3) NR 14.8 (14.4) NR
  FTD, n = 69 43.4 (17.4) NR 21.1 (19.8) NR
 Saltzman [44]
Concomitant MAT + ACL n = 40
44 (16) 67 (22) 23 (NR) < 0.01
 Riboh et al. [38] n = 32 (subset of Cole 
study)
40.2(19) n = 27 65.0 (17.7) n = 23 24.8 (NR) < 0.0001
 Stone et al. [48] n = 115 45 (n = 66) 70 (n = 15) 25 (NR) < 0.001
 Stone et al. [49] n = 49 Medianb 48 75 27 (NR) 0.001
Baseline Endpoint p value
Tegner
 Cole et al. [13] 5.0 (2.8) 6.5 (2.7) < 0.05
 González-Lucena et al. [17] 3.1 (2.1) 5.5 (2.1) < 0.001
 Marcacci et al. [28] 3 (IQR 3.5) 5 (IQR3–6) 0.012
 Rue et al. [42] 5.0 (3.3) 6.7 (2.3) 0.001
 Stone et al. [49] (medians) 2.8 5.2 n.s.
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Lee et al. [25] also report benefit from MAT in patients 
with advanced bipolar chondral lesions, with no differ-
ence in post-operative Lysholm scores between those with 
baseline ICRS scores ≤ 2 and those with more advanced 
chondral damage (baseline data not provided for sub-
groups). Clinical failure rates were not significantly dif-
ferent (low grade damage 7%, high grade 5%, but there 
were small numbers and wide CIs), but graft survival 
rates by MRI or follow-up arthroscopy showed a much 
lower survival rate in the group with high-grade lesions 
on both sides at baseline (62%) compared to those with 
low-grade lesions (94%).
One study each reported the Knee Society Score (KSS) 
[23] and Hospital for Special Surgery (HSS) score [54] 
and reported statistically significant improvements.
Quality of life
Six studies [2, 13, 28, 38, 42, 44] (Table 6) reported QoL 
using Short-Form 36 (SF36) or the shorter subset, SF-12. 
One [44] found no significant differences Cole et al. [13] 
and Riboh et al. [38] found improvements in the physical 
but not mental scores, as did Abrams et al. [2] in a group 
having combined MAT and osteochondral allografts. Rue 
et al. [42] found a statistically significant improvement 
in the physical SF-12 only in the subgroup that had com-
bined MAT and autologous chondrocyte implantation. 
Both physical and mental components were significantly 
improved in the study by Marcacci et al. [28] which was 
rated highly, based on appropriate selection of partici-
pants, sample size calculation, blinding of outcome asses-
sors and no losses to follow-up.
Subgroups: medial vs lateral MAT
Nine studies [1, 13, 17, 24, 28, 42, 43, 51, 54] assessed 
medial and lateral MATs separately (Supplementary file, 
Table 7) for at least one functional or quality of life outcome, 
but only one [43] found statistically significant differences 
in functional outcomes or quality of life between medial and 
lateral MAT, in a group of patients having combined MAT 
and anterior cruciate ligament reconstruction, with only 
seven patients in the lateral group. In an earlier paper from 
the same group, Cole et al. [13] commented that the lateral 
Table 5  Functional outcomes 
by baseline joint state
OCS Outerbridge Cartilage Score
Chondral surface good, 
n = 60
Chondral 
surface bare 
n = 39
Kempshall et al. [22]
 Lysholm knee score at final endpoint, mean (SD)a
  Baseline value 58.6 (4.8) 47.3 (6.6)
  Endpoint value 80.2 (5.0) 71.4 (7.8)
  p value < 0.001 < 0.001
 IKDC score at final endpoint, mean (SD)
  Baseline value 43.13 (4.1) 37.3 (5.3)
  Endpoint value 68.8 (5.5) 58.7 (8.2)
  p value < 0.001 < 0.001
 Tegner score at final endpoint, median (range)
  Baseline value 2 (0–7) 2 (0–9)
  Endpoint value 4 (1–10) 4 (1–9)
  p value < 0.05 < 0.05
Mahmoud et al. [27] OCS 0–2 OCS 3–4
 Lysholm knee score
  Change from baseline + 21.3 +24.5
  p value 0.013 < 0.001
 IKDC
  Change from baseline 10.8 21.5
  p value 0.241 0.001
 Tegner
  Change from baseline 1.73 0.53
  p value 0.015 n.s.
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subgroup showed a trend toward greater improvements than 
the medial subgroup on nearly all knee scoring scales.
Eight studies [23, 32, 33, 35, 43, 48, 53, 54] reported 
survival outcomes for medial and lateral MAT, six showing 
no statistically significant differences. Parkinson et al. [35] 
found increased graft survival with lateral MAT (89% at 
5 years versus 62% for medial, p = 0.026) (Supplementary 
File Table 8). Kim et al. [23] reported 13% of failures in lat-
eral MAT compared to 3.7% in medial MAT, but the medial 
figure was based on only one patient, and some patients were 
classed as failures because of MRI findings despite satisfac-
tory Lysholm scores. Van der Wal et al. [53] did not present 
statistical analysis, but failure rates were higher in the medial 
subgroup (35%) than the lateral (25%) and time to failures 
was shorter (mean 82 months medial versus 161 months 
lateral). Verdonk et al. [54] reported 28% failures in medial 
MAT compared to 16% in lateral MAT, but the difference 
was not statistically significant.
Subgroups: combined procedures
Seven studies considered concurrent procedures [13, 17, 24, 
28, 32, 33, 42] (see also supplementary file Tables 9 and 10). 
Most studies found no statistically significant differences 
between those undergoing isolated MAT or MAT combined 
with other concurrent procedures on either functional, qual-
ity of life or survival estimates. However, Noyes et al. [32] 
found a statistically significantly poorer survival time in 
knees that required a concurrent osteochondral autograft 
transfer, compared to those that did not. Rue et al. [42] 
noted differences in IKDC score between those undergoing 
MAT + ACI and MAT + OA transplantation, however there 
was also an imbalance in scores at baseline. Noyes et al. 
[33] also reported analysis of those having ligament recon-
struction or osteochondral autografts, and those having MAT 
alone, and found no significant differences.
Meniscectomy versus no meniscectomy
Li et al. [26] compared two groups of meniscectomised 
patients, one group having MAT and the other not. About 
half of the MAT group had allografts inserted at the time 
of meniscectomy. The rest had MAT on average 3 years 
later because of pain in the knee. At average follow-up of 
54 months (minimum 40 months), clinical results were 
similar, but there was less radiographic change in the MAT 
group. The study was too small and too short duration to 
compare immediate versus delayed MAT.
Table 6  Quality of life in MAT studies
a Outcomes assessed at 2 years, not mean follow-up of 2.9 years, results described as mean (95% CI)
b Estimated from figure
Outcomes, mean (SD) Kempshall et al. [22]a Cole et al. [13] Marcacci [28] Rue [42] Abrams et al. [3] Riboh [38]
Chondral 
surface good 
n = 60
Chondral sur-
face bare n = 39
n = 36 n = 32 n = 28 n = 32
KOOS QoL
 Baseline value 28.9 (5.0) 22.4 (5.0) 26b 25.2 (18.9)
 Endpoint value 52.7 (7.1) 45.0 (8.1) 50b 55.1 (20.4)
 p value p < 0.001 p < 0.001 p = 0.16 <0.001
SF-12/36 physical SF-36 SF-36 SF-12
 Baseline value 40b 37.3 (7.2) 38.9 (7.3) 38.6 (6.6)
 Endpoint value 48b 49.7 (8.3) 44.0 (5.5) 46.6 (6.8)
 p value p < 0.05 p < 0.0001 0.001
SF-12/36 mental SF-36 SF-36 SF-12 SF12
 Baseline value 50b 49.7 (10.8) 55.5 (9.4) 54.0 (11.7)
 Endpoint value 55b 53.5 (7.5) 55.2 (8.2) 55.8 (8.0)
 Change value NR NR p < 0.34
 p value p = ns p = 0.0032
SF-12 overall
 Baseline value 43.5 (5.6)
 Endpoint value 46.6 (5.9)
 p value 0.041
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Return to sport
Saltzman et al. [44] and Stone et al. [49] reported return to 
sport. In the subgroup having concomitant MAT and ACL 
reconstruction in the Saltzman et al. study [44], 19 partici-
pants self-identified as athletes and 50% of these returned to 
sports, 39% at the same level as previously. Of 10 who had 
been involved in competitive sport, 50% returned to sport 
at the same level. This study was assessed as fair quality, 
although note that the sample for these outcomes was small. 
Stone et al. [49] reported that 74% of the 49 participants in 
their study were able to participate in sport.
Adverse events
Complications were generally infrequent. Van Arkel et al. 
[51] reported no major complications and only five minor 
ones amongst 63 grafts, these being irritation around non-
absorbable sutures. Three studies reported a need to resolve 
flexion problems by manipulation or arthrolysis a few weeks 
after MAT in four of 38 patients [33], one of 32 patients [28] 
and one of 32 patients [38]. Stone et al. [48] reported four 
infections amongst 115 patients, and Saltzman et al. [44] 
reported two minor infections in 40 patients. LaPrade et al. 
[24] reported one late infection but it appears unrelated.
Kempshall et al. [22] reported major complications in 
17% of the ‘chondral surface good’ group and 38% of the 
‘chondral surface bare’ group, this included tear of the allo-
graft in 13% and 31%, respectively. Abat at al [1] reported 
total complication rates of 33.3% of the only-suture group 
and 16.4% of the bony-fixation group. Three studies reported 
that no complications occurred [2, 13, 42] and in one study 
adverse events were not reported [11].
Assessing the cost‑effectiveness of meniscal allograft 
transplantation
The benefits of MAT could include symptomatic relief and 
restoration of at least some previous activities, which will be 
reflected in utility values, and in the longer term, prevention 
or delay of osteoarthritis, and avoidance or postponement of 
some knee replacements, with resulting savings.
The costs include the initial procedure, the cost of the 
allograft, and any subsequent surgery, including arthroscopic 
debridement if the graft has to be removed, and possibly 
insertion of a second MAT.
For cost-effectiveness analysis, data are needed for both 
patients having MAT, and a comparison group that does not 
have MAT after meniscectomy, as follow:
• Quality of life expressed as a utility measure using a 
generic preference-based measure such as EQ-5D-5L, or 
a clinical outcome score such as WOMAC, from which 
we can map to EQ-5D. This captures symptomatic relief 
and return to activities. (Though EQ-5D may not capture 
all the utility of return to sport since it is based more on 
activities of daily living.) Increasing OA would reduce 
quality of life over time.
• Costs of MAT including rehabilitation.
• Costs of MAT failure, including if appropriate, repeat 
MAT. A second MAT in the same compartment is 
uncommon [29, 32, 43, 49, 52]. However if a first MAT 
in a young person lasted for, say, 10 years, providing 
symptomatic relief, there could be a case for a repeat 
MAT, perhaps as an interim intervention pending knee 
arthroplasty.
• Costs of conservative care for people not having MAT, 
including physiotherapy and drug costs. In this case, 
“physiotherapy” would need to be carefully defined, 
since it is an umbrella term covering many different 
forms of treatment, and a personalised knee therapy 
intervention for the meniscal deficient knee may be more 
effective. (See pilot RCT by Smith et al. [47]).
• Costs of advanced OA, principally TKA, for both groups. 
This will depend on proportions having TKA.
However, data are lacking on:
• What proportion of people who do not get MAT, develop 
advanced OA requiring TKA, and when. It is assumed 
that surgeons will be reluctant to do TKA before age 55.
• What proportion of people who do get MAT, develop 
advanced OA requiring TKA, and when.
Almost all the studies of MAT are observational ones 
with no non-MAT control groups. However Smith et al. 
[47] have reported the results of a pilot RCT of MAT versus 
personalised physiotherapy. At 12 months, KOOS scores 
improved in both groups but the improvement in the MAT 
group was roughly double that in the physiotherapy group—
a difference of 12 in composite KOOS (p = 0.03). Other 
scores improved more in the MAT group but without reach-
ing statistical significance. Smith et al. advocate caution in 
interpretation due to small numbers (21 randomised, plus a 
preference group of 15), the short follow-up, and possible 
effects of the three osteotomies in the MAT group but none 
in the physiotherapy group. They use the data to estimate 
that a trial with 50 patients in each arm would be required 
to give a definitive result.
Discussion
There seems to be no doubt that meniscectomy, whether 
total or partial, leads to OA in the longer term. However, it 
is not yet proven whether MAT is chondroprotective. With 
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the data currently available, it does not appear possible to 
do a full assessment of the cost-effectiveness of MAT. The 
main problem is the lack of control groups, having active 
conservative care. MAT is probably better, but for cost-
effectiveness analysis we need to know the effect size—how 
much better is it?
The people who get significant problems after meniscec-
tomy may be a small subset, perhaps only 10–20% of all 
having meniscectomy. Those who present with significant 
symptoms with or without radiological evidence of OA at 
5–10 years after meniscectomy, may have other risk factors. 
It is assumed that people having MAT have had a traumatic 
meniscal tear and subsequent meniscectomy, and that they 
do not come from the older group with degenerate menisci, 
whose natural history is different (and who should not be 
used as a natural history comparison group).
To compare outcomes of MAT and non-MAT, data are 
needed on how people are selected for MAT in order to 
identify a comparable group of people in non-MAT natural 
history studies. In some MAT studies, patients with more 
severe knee problems such as existing OA, or advanced KL 
grades, are excluded. So some non-MAT people may have a 
more severe mix of knee problems. If so, comparing a MAT 
cohort with people who do not get MAT after meniscectomy, 
may favour MAT. But more likely, if the MAT group are a 
small subset of all people who have had meniscectomy, and 
who are doing worse, then a comparison with a non-MAT 
group may under-estimate the benefits of MAT.
The likelihood of success is greater in those with less 
damage to the articular cartilage. A particularly difficult 
group are young people with ICRS grade 3 lesions in whom 
conservative treatment has failed, and who are much too 
young for knee replacement. Two options have been tried. 
One is the “biological knee replacement” combining MAT 
with ACI as reported by Bhosale et al. [9] from Oswestry, 
but with a series of only eight patients. The other is to com-
bine MAT with osteochondral allografts, as reported by 
Abrams et al. [2] and Frank et al. [15].
However, the results of the study by Kempshall et al. and 
Parkinson et al. [22, 35] show that in patients with more 
severe “bone on bone” defects, MAT may not be as suc-
cessful as in people with lesser defects, but can still provide 
benefit. It is possible that MAT may be both less successful 
and more cost-effective in the more severe group because 
they have more to gain. The gains in symptom scores were 
of similar magnitude but the severe group started from a 
lower baseline.
A short-term before and after analysis could compare 
quality of life using an instrument that can be converted to 
a utility measure, such as WOMAC or SF-12, and assess-
ing the cost per quality-adjusted life year (QALY) gained 
from the quality of life gains. However, the improvements 
may be due to MAT, or associated rehabilitation, or some 
natural recovery, or by patients learning to live with the 
problem, for example by reducing activities. Data are lack-
ing data on what benefits the non-MAT measures might 
provide for non-MAT patients. They would be expected to 
benefit from physiotherapy, if they get it. But if the MAT 
group got physiotherapy and the non-MAT group did not, it 
would not be clear whether any benefits were due to MAT 
or physiotherapy.
So a before and after analysis could be misleading, and 
favourable to MAT. However the pilot RCT by Smith et al. 
[47] reported that MAT had advantages over conservative 
care with personalised physiotherapy.
A study by Bendich et al. [8] has addressed this prob-
lem. They noted that there was uncertainty about the chon-
droprotective effect of MAT [41, 46, 52]. They then asked 
how effective MAT would have to be, to be cost-effective. 
They start by assuming that after meniscectomy, progres-
sion to severe OA (bad enough for TKA to be considered) 
would be 1.8% a year, based on the study by Englund et al. 
[14], but they then do sensitivity analyses around that 
figure, with higher and lower progression rates. In their 
primary “base case” analysis, patients are aged 30, with 
no OA, and BMI 20. They test various other scenarios, 
with older or heavier patients, and different ages at which 
TKA would be performed. They also test different costs 
of MAT, TKA and of non-operative care.
In their base case, they estimate that MAT would have 
to reduce progression to severe OA by 31%, from 1.8% a 
year to 1.2% a year. However in patients with higher BMIs, 
who are at increased risk of progression to OA, the reduc-
tions need only be 16% in the BMI 25–30 group, and 10% 
in the BMI over 30 group, for MAT to be cost-effective. 
Their base case age was 30. In patients aged 20–29 (who 
would have to wait much longer for TKA), the reduction 
in progression for MAT to be cost-effective was only 25%, 
whereas in the 40–49 age group, the reduction in progres-
sion would need to be 41%.
The costs used were from the USA, including TKA cost 
of $26,452, and only slightly higher for revision TKA. 
Costs in other countries would be different. They assumed 
cost of MAT to be $8202.
In their base case, they assumed no OA, whereas we 
know that many people who have needed meniscectomy 
have sustained articular cartilage damage. In those peo-
ple, progression to OA would be faster, and cost-effective-
ness of MAT greater. They do not give details of interval 
between meniscectomy and MAT. Their benefits focus on 
reducing progression to OA and joint replacement, rather 
than on relief of symptoms after meniscectomy.
The pilot RCT by Smith et al. [47] showed greater ben-
efit with MAT than personalised physiotherapy and it may 
be that MAT could be shown to be cost-effective based on 
utility gain from symptom relief alone, with taking into 
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account future cost of TKA avoided. A similar but much 
larger and longer trial is needed to confirm this.
As outlined above, there appears to be a subgroup that 
do particularly badly after meniscal tears and subsequent 
meniscectomy. MAT would be much more cost-effective 
in this group, so a high research priority is how to identify 
them at or soon after meniscectomy, and to see if inter-
vention soon after meniscectomy gave better result than 
waiting for symptoms to develop.
Research priorities include the need for randomised con-
trolled trial evidence for the effectiveness of MAT compared 
with conservative care in short-term effectiveness, and also 
the long-term potential to change the natural history after 
meniscal loss. Further research is also warranted on the best 
choice of graft, surgical technique, and optimal rehabilita-
tion after surgery.
Conclusions
There were three issues to be considered:
1. Does meniscal deficiency lead to early osteoarthritis? 
Yes.
2. Does MAT prevent or delay OA after meniscectomy? 
There is a lack of good evidence on this, so the verdict 
at present is “not proven”.
3. Is MAT an effective and cost-effective way of relieving 
continuing symptoms after meniscectomy? It appears 
effective, but the effectiveness of MAT compared to con-
servative management is uncertain, with only the one 
small RCT providing short-term evidence.
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